Genetic analysis of 280 children with unexplained developmental delay or intellectual disability using whole exome sequencing Authors: Jinbo Xu, Wei Su, Yishan Wang, Yuanyuan Luo, Fuling Ye, Yanhong Xu, Lulu Chen, Hong Li Published: 2024 ABSTRACT AbstractIntroductionDevelopmental delay (DD) and intellectual disability (ID) are key manifestations of neurodevelopmental disorders (NDDs), characterized by considerable clinical and genetic variability, which complicates genetic diagnosis. Whole exome sequencing (WES) has become an effective method for uncovering genetic causes in patients with unexplained DD/ID.MethodsWe retrospectively analyzed WES data from 280 patients diagnosed with unexplained DD/ID. Demographic information and genetic variants identified through WES were assessed, along with an evaluation of clinical factors that might influence the detection of genetic causes.ResultsPathogenic variants were detected in 73 cases (36.07%), including 25 cases involving pathogenic chromosomal copy number variations. Clinical factors such as age, sex, gestational age, birth weight, anoxia, jaundice, associated symptoms, family history, muscle strength, muscle tone, epilepsy, brain MRI findings, EEG results, and the severity of DD/ID did not significantly impact the WES outcomes. However, a significant correlation was observed between delivery mode and positive WES results, with a higher diagnostic yield among patients delivered via caesarean section.ConclusionsWES is a valuable approach for identifying genetic causes in patients with unexplained DD/ID, providing benefits for patient management, family genetic counseling, and long-term prognosis assessment.Clinical trial numberNot applicable.Keywords: Whole exome sequencing, Developmental delay, Intellectual disability, Genetic diagnosis, Neurodevelopmental disorders Introduction Developmental delay (DD) and intellectual disability (ID) represent major manifestations of neurodevelopmental disorders (NDDs), with a global prevalence ranging from 1.1 to 32% [1, 2]. DD/ID manifests through a variety of phenotypic manifestations and is frequently linked to conditions such as autism spectrum disorders, attention-deficit/hyperactivity disorder, neurodevelopmental motor disorders and congenital developmental structural abnormalities. The considerable clinical and genetic heterogeneity associated with DD/ID poses significant challenges in achieving a genetic diagnosis. Current data suggest that genetic factors contribute to approximately 50% of cases of unexplained DD/ID, with moderate and severe cases accounting for nearly 70% or more of these instances. Moreover, over 1000 genes have been identified as being associated with the DD/ID phenotype [3]. As second-generation sequencing technologies rapidly advance, the approach to diagnosing unexplained DD/ID has evolved from using copy number variation sequencing (CNV-seq) to whole exome sequencing (WES). WES enables the detection of single nucleotide variations (SNVs) and chromosomal copy number variations (CNVs) through whole-exome capture and massively parallel DNA sequencing. Additionally, it targets more candidate genes linked to DD/ID and identifies novel splicing sites that could be disease-causing upon data reanalysis [4]. WES is also advocated as a first-tier clinical diagnostic test for individuals with NDDs, offering an overall diagnostic yield of 36%, which surpasses the diagnostic yield of Chromosomal microarray analysis (CMA) (15–20%) [5]. Given the increasing application of WES in clinical practice, we have documented our comprehensive experience utilizing this technology for diagnosis at a tertiary hospital in China over a three-year period. The clinical symptoms and gene mutations observed in the children were analyzed to provide a theoretical foundation for the clinical diagnosis of DD/ID with unknown causes. Methods Patients We conducted a retrospective analysis of patients aged 1–18 years who were seen at Anhui Provincial Children’s Hospital between January 2021 and December 2023. The study cohort comprised 280 Chinese children diagnosed with either DD or ID of unknown etiology. DD was defined as a marked delay in reaching early childhood developmental milestones in children younger than 5 years. Global DD was diagnosed in young children using the Griffiths Development Scales-Chinese, identifying delays in two or more developmental areas, including gross motor skills, fine motor skills, social and personal development, language, and cognitive function [6]. Additionally, intellectual disability was defined by an intelligence quotient (IQ) score below 70 in children aged 5 years and older, with associated impairments in cognitive function and adaptive behavior, as measured by the Wechsler Intelligence Scale for Children, 4th edition, Chinese version [7]. Clinical information for each patient was obtained by thoroughly reviewing their medical records. We examined birth history, paying particular attention to delivery mode, gestational age, birth weight, and perinatal health issues such as anoxia and jaundice. Physical and neurological assessments were conducted, focusing on specific facial and limb anomalies, including microcephaly, micrognathia, single transverse palmar crease, polydactyly, and skin lesions. Myodynamia and muscle tone were carefully evaluated during the neurologic examination. The family history survey encompassed consanguineous marriages, siblings with developmental abnormalities, and immediate relatives with mental retardation. In addition to investigating neurological comorbidities such as epilepsy, we also assessed structural or functional abnormalities across various systems, including the cardiovascular and digestive systems. Neuroimaging studies, including brain magnetic resonance imaging (MRI), electroencephalography (EEG), and the history of genetic testing were performed on selected patients. Whole-exome sequencing and data analysis Genomic DNA was extracted from blood samples of patients and their parents for WES using the SureSelect Human All Exon Kit on the Illumina NovaSeq 6000 platform. Sequencing reads were aligned to the human reference genome, with stringent coverage requirements, and variants were identified using the Genome Analysis Toolkit (GATK) and annotated through ANNOVAR [8]. These variants were cross-referenced with multiple databases, including dbSNP and gnomAD, and pathogenicity predictions were made using tools like PROVEAN and PolyPhen-2. Sanger sequencing was performed to validate WES findings by amplifying and sequencing candidate variants. Additionally, copy number variations (CNVs) were detected using tools like XHMM and CNVKit, with further validation conducted through methods such as multiplex ligation-dependent probe amplification (MLPA) or quantitative polymerase chain reaction (qPCR) [9, 10]. Variants were classified following ACMG guidelines, focusing on those with a minor allele frequency below 0.05 for further analysis [11]. Statistical analysis Statistical analyses were conducted using IBM SPSS version 22.0. Clinical data from patients with or without exome-positive results were analyzed using the Chi-square test or Fisher’s exact test, while the Mann–Whitney U test was employed to compare median values. A p-value of < 0.05 was considered statistically significant. Results Identification of pathogenic by WES In the WES results of 280 patients, 48 variants were classified as pathogenic, 46 as likely pathogenic, 5 as likely benign, and 150 as variants of unknown significance, while 31 specimens showed no detectable results (Table 1). Among the pathogenic variants, 30 were autosomal dominant (62.50%), 10 were autosomal recessive (20.83%), 6 were X-linked (12.50%), and 2 were both autosomal dominant/recessive (AD/AR) (4.17%). In the 41 families that underwent trio-based Sanger sequencing, de novo mutations were detected in 32 cases, with 3 cases showing paternal mutations and 4 cases maternal mutations. Additionally, one case involved two variants in the MMACHC gene, inherited from both parents, leading to Methylmalonic aciduria and homocystinuria, cblC type (MIM: 277400). Another case involved Bart-Pumphrey syndrome (MIM: 149200) due to mutations in the GJB2 gene, identical to the variant found in the patient’s parents. A further case of Bart-Pumphrey syndrome was also linked to mutations in the GJB2 gene, inherited from the father; this patient was conceived through IVF, and the same gene variant was identified in his twin brother. Table 1List of pathogenic variants identified by WESpatientSexAgeACMG classGeneVariantVariant typeZygosityOMIM Phenotype (MIM#)InheritanceFamily-based trio Sanger sequencingCarrier/Diagnosed1M1 yearsPSMN1NM_004006.3:exon7-exon8:del-hetSpinal muscular atrophy-2 (253550)ARNDCarrier2M3 yearsPBBS1NM_024649.5:c.1285 C > T:p.R429*Stop gainedhomBaedet-Biedl syndrome (209900)ARNDDiagnosed3F2 yearsPPTSNM_000317.3:c.259 C > T:p.P87SMissensehetHyperphenylalaninemia, BH4-deficient, A (264070)ARNDCarrier4F7 monthsPMMACHCNM_015506.3:c.80 A > G:p.Q27RNM_015506.3:c.609G > A:p.W203*Missense;Stop gainedhet;hetMethylmalonic aciduria and homocystinuria, cblC type (277400)ARPaternal; maternalDiagnosed5M1 yearsPPIK3R2NM_005027.4:c.1117G > A:p.G373RMissensehetMegalencephaly-polymicrogyria-polydactyly-hydrocephalus (603387)ADde novoDiagnosed6M9 yearsPATP7BNM_000053.4:c.2333G > T:p.R778LMissensehetWilson disease (277900)ARNDCarrier7F3 yearsPFOXG1NM_005249.5:c.1247dupA: p.Y416*Stop gainedhetRett syndrome, congenital variant (613454)ADde novoDiagnosed8M3 yearsPFBXO11NM_025133.4:c.1976-1(IVS18)G > ASplicinghetIntellectual developmental disorder with dysmorphic facies and behavioral abnormalities (618089)ADde novoDiagnosed9F2 yearsPPAFAH1BNM_000430.4:c.967T > C:p.W323RMissensehetLissencephaly 1 (607432)ADNDDiagnosed10M2 yearsPSPG11NM_025137.4:c.2163dupT: p.I722Yfs*10FrameshifthetSpastic paraplegia 11, autosomal recessive (604360)ARNDCarrier11M1 yearsPZEB2NM_014795.4:c.2866 C > T:p.Q956*Stop gainedhetMowat-Wilson syndrome (235730)ADde novoDiagnosed12F1 yearsPTAOK1NM_020791.4:c.2104 C > T:p.R702*Stop gainedhetDevelopmental delay with or without intellectual impairment or behavioral abnormalities (619575)ADde novoDiagnosed13M10 monthsPFOXP1NM_001349338.3:c.1561 A > T:p.K521*Stop gainedhetIntellectual developmental disorder with language impairment with or without autistic features (613670)ADde novoDiagnosed14F5 yearsPMECP2MM_004992.4:exon3-exon4:del-hetIntellectual developmental disorder, X-linked syndromic, Lubs type (300260)XLDde novoDiagnosed15F4 yearsPTUBB4ANM_006087.4:c.763G > A:p.V2551MissensehetLeukodystrophy, hypomyelinating,6 (612438)ADde novoDiagnosed16M6 yearsPPAHNM_000277.3:c.532G > A:p.E178KMissensehetPhenylketonuria (261600)ARmaternalCarrier17F7 monthsPTCF4NM_001083962.2:c.1739G > A:p.R580QMissensehetPitt-Hopkins syndrome (610954)ADde novoDiagnosed18F3 yearsPCLTCNM_004859.4:c.2746dup: p.L916Pfs*7FrameshifthetIntellectual developmental disorder, autosomal dominant 56 (617854)ADde novoDiagnosed19M6 yearsPDMDNM_004006.3:exon46-exon51:del-hemDuchenne muscular dystrophy (310200)XLRNDDiagnosed20M6 monthsPGRIN1NM_007327.4:c.1921 A > G:p.M641VMissensehetNeurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant (614254)ADde novoDiagnosed21F1 yearsPMECP2NM_004992.4:c.880 C > T:p.R294*Stop gainedhetIntellectual developmental disorder, X-linked syndromic, Lubs type (300260)XLDde novoDiagnosed22F1 yearsPFOXG1NM_005249.5:c.460dup: p.E154Gfs*301FrameshifthetRett syndrome, congenital variant (613454)ADde novoDiagnosed23M3 yearsPKIF1ANM_004321.8:c.1031 C > T:p.T344MMissensehetNESCAV syndrome (614255)ADde novoDiagnosed24M1 yearsPFOXG1NM_005249.5:c.460del: p.E154Rfs*38FrameshifthetRett syndrome, congenital variant (613454)ADde novoDiagnosed25M3 yearsPFOXP1NM_032682.6:c.1653-1(IVS18)G > ASplicinghetIntellectual developmental disorder with language impairment with or without autistic features (613670)ADde novoDiagnosed26F5 yearsPPPP3CANM_000944.5:c.1339G > A:p.A447TMissensehetDevelopmental and epileptic encephalopathy 91 (617711)ADde novoDiagnosed27M4 monthsPGJB2NM_004004.6:c.235del: p.L79Cfs*3FrameshifthomBart-Pumphrey syndrome (149200)ADPaternal; maternalDiagnosed28F5 monthsPITPR1NM_002222.7:c.835 A > G:p.K279EMissensehetGillespie syndrome (206700)ADmaternalDiagnosed29F4 yearsPATP1A3NM_152296.5:c.958G > A:p.A320TMissensehetAlternating hemiplegia of childhood 2 (614820)ADde novoDiagnosed30M5 yearsPMECP2NM_004992.4:c.1164_1207del: p.P389*Stop gainedhemIntellectual developmental disorder, X-linked syndromic, Lubs type (300260)XLDmaternalDiagnosed31M5 yearsPKCNB1NM_004975.4:c.934 C > T:p.R312CMissensehetDevelopmental and epileptic encephalopathy 26 (616056)ADde novoDiagnosed32F5 yearsPSTXBP1NM_003165.6:c.37 + 2(IVS1)T > GSplicinghetDevelopmental and epileptic encephalopathy 4 (612164)AD/ARde novoDiagnosed33M1 years 7 monthsPMECP2NM_004992.4:c.925 C > T:p.R309WMissensehemIntellectual developmental disorder, X-linked syndromic, Lubs type (300260)XLDde novoDiagnosed34M1 years 4 monthsPTCF20NM_005650.4:c.3376 C > T:p.Q1126*Stop gainedhetDevelopmental delay with variable intellectual impairment and behavioral abnormalities (618430)ADde novoDiagnosed35F2 yearsPSTXBP1NM_003165.6:c.103 C > T:p.Q35*Stop gainedhetDevelopmental and epileptic encephalopathy 4 (612164)AD/ARde novoDiagnosed36M1 years 5 monthsPGABBR2NM_005458.8:c.1699G > A:p.A567TMissensehetDevelopmental and epileptic encephalopathy 59 (617904)ADde novoDiagnosed37F1 yearsPDHX30NM_138615.3:c.2344 C > T:p.R782WMissensehetNeurodevelopmental disorder with variable motor and speech impairment (617804)ADde novoDiagnosed38F10 monthsPKIF1ANM_004321.8:c.4711 C > T:p.R1571*Stop gainedhetNESCAV syndrome (614255)ADde novoDiagnosed39M6 yearsPACVR1NM_001105.5:c.617G > A:p.R206H;MissensehetFibrodysplasia ossificans progressiva (135100)ADde novoDiagnosed40F2 yearsPSETBP1NM_015559.3:c.1843 C > T:p.R615*Stop gainedhetIntellectual developmental disorder, autosomal dominant 29 (616078)ADde novoDiagnosed41M4 yearsPAFF3NM_002285.3:c.697G > A:p.A233TMissensemosaicismKINSSHIP syndrome (619297)ADde novoDiagnosed42F4 yearsPCTNNB1NM_001904.4:c.1420 C > T:p.R474*Stop gainedhetNeurodevelopmental disorder with spastic diplegia and visual defects (615075)ADde novoDiagnosed43F4 yearsPMTRFRNM_152269.5:c.394 C > T:p.R132*Stop gainedhetSpastic paraplegia 55, autosomal recessive (615035)ARmaternalCarrier44M5yearsPFOXP2NM_014491.4:c.1432 C > T:p.R478*Stop gainedhetSpeech-language disorder-1 (602081)ADde novoDiagnosed45M2 years 3 monthsPGALCNM_000153.4:c.1901T > C:p.L634SMissensehetKrabbe disease (245200)ARpaternalCarrier46M3 yearsPGJB2NM_004004.6:c.109G > A:p.V37IMissensehetBart-Pumphrey syndrome (149200)ADpaternalDiagnosed47M2 monthsPSMPD1NM_000543.5:c.842_849dup: p.H284Sfs*18FrameshifthetNiemann-Pick disease, type A (257200)ARpaternalCarrier48F4 yearsPTFE3NM_006521.6:c.350G > A:p.R117QMissensehetIntellectual developmental disorder, X-linked syndromic, with pigmentary mosaicism and coarse facies (301066)XLRde novoCarrierP: pathogenic variant; het: heterozygosity; hom: homozygote; hem: hemizygosity; ND: not done; AD: autosomal dominant; AR: autosomal recessive; XLD: X-linked dominant; XLR: X-linked recessive List of pathogenic variants identified by WES NM_015506.3:c.80 A > G:p.Q27R NM_015506.3:c.609G > A:p.W203* Missense ;Stop gained het; het P: pathogenic variant; het: heterozygosity; hom: homozygote; hem: hemizygosity; ND: not done; AD: autosomal dominant; AR: autosomal recessive; XLD: X-linked dominant; XLR: X-linked recessive Among the genetic disorders identified, 4 cases were Intellectual developmental disorder, X-linked syndromic, Lubs type (MIM: 300260) caused by mutations in the MECP2 gene, 3 cases were Rett syndrome, congenital variant (MIM: 613454) due to mutations in the FOXG1 gene, 2 cases were Developmental and epileptic encephalopathy 4 (MIM: 612164) linked to mutations in the STXBP1 gene, 2 cases were NESCAV syndrome (MIM: 614255) resulting from mutations in the KIF1A gene, and 2 cases were intellectual developmental disorder with language impairment, with or without autistic features (MIM: 613670), associated with mutations in the FOXP1 gene. In addition, 25 CNVs ranging in size from 3.56 kb to 0.50 Mb were identified using WES data (Table 2). The number of protein-coding genes involved in these CNVs ranged from 1 to 177. All identified CNVs overlapped with previously described CNVs and were interpreted as pathogenic. Thus, WES has proven effective in identifying pathogenic CNVs in patients with DD/ID. Table 2Summary of copy number variants identified by whole-exome sequencingPatientACMGclassChromosomal locationGenomic coordinatesTypeLengthRtotein coding genesOMIM Phenotype (MIM#)Inheritance1PXq28152900965_15384630Duplication0.95 Mb40Chromosome Xq28 duplication syndrome (300815)maternal2PXp22.33p21.1200837_34675174Deletion34.47 Mb143-de novo3P9p24.3p22.1134923_18574373Deletion18.44 Mb53-de novo4P10q26.2-q26.3;10p15.3-p12.31126,009,053–133,659,695;46887-20068239Deletion;duplication7.65 Mb;20.02 Mb42;80-de novo;de novo5P17p11.216,849,989–20,516,122Duplication3.67 Mb44Potocki-Lupski syndrome (610883)de novo6P7q11.2373,225,548–74,758,855Deletion1.53 Mb24Williams-Beuren syndrome (194050)de novo7P10p15.346887-1200147Deletion1.15 Mb9Intellectual developmental disorder, autosomal dominant 30 (616083)de novo8P12p13.33-p11.221,795,074–27,697,705Duplication25.90 Mb177-de novo9PXq22.1-q22.2102,937,318–103,832,257Duplication0.89 Mb8Pelizaeus-Merzbacher disease (312028)maternal10P22q13.2-q13.3342,893,456–50,799,128Deletion7.91 Mb68Phelan-mcdermid syndrome (606232)de novo11P18p11.32-q11.147220-20950083Duplication20.9 Mb50Tetrasomy 18p syndrome ( 614290)de novo12P15q11.222,460,820–23,039,543Deletion0.58 Mb4Chromosome 15q11.2 deletion syndrome (615656)maternal13P15q11.2-q13.322,427,578–32,172,521Duplication9.74 Mb2915q11-q13duplication syndrome (608636 )de novo14P9p24.3-p2316965-9397482Deletion9.38 Mb38-de novo15P17q1234,440,000–36,250,000Duplication1.81 Mb1917q12 duplication syndrome (614526 )maternal16P1q21.1-q21.2146,877,595–148,483,252Duplication1.61 Mb11chromosome 1q21.1 duplication syndrome (612475 )unknow17P13q33.3-q34106,543,235–114,327,491Deletion7.78 Mb38Chromosome 13q33-q34 deletion syndrome (619148)de novo18P15q11.1-q13.319,964,677–32,393,570Duplication12.43 Mb31Chromosome 15q11-q13 duplication syndrome (608636 )unknow19P17p11.216,939,400–20,522,126Duplication3.58 Mb44Potocki-Lupski syndrome (610883 )de novo20P16p12.1-p11.228,471,084–30,188,698Deletion1.72 Mb46Chromosome 16p11.2 deletion syndrome (611913)de novo21PXq25123,671,504–124,737,921Duplication1.07 Mb6Chromosome Xq25 duplication syndrome (300979)maternal22P7q11.2373,198,601–74,743,520Deletion1.54 Mb23Williams syndrome (185500)de novo23PXq23111,182,533–111,681,169Deletion0.50 Mb4Lissencephaly, X-linked (300067)de novo24P1q21.3153,816,273–153,819,835Deletion3.56Kb1GAND syndrome (615074)de novo25P22q11.23-q12.225,351,374–30,094,003Deletion4.74 Mb36Schwannomatosis, vestibular (101000)de novoP: pathogenic variant Summary of copy number variants identified by whole-exome sequencing 10q26.2-q26.3; 10p15.3-p12.31 126,009,053–133,659,695; 46887-20068239 Deletion; duplication 7.65 Mb; 20.02 Mb 42; 80 de novo; de novo P: pathogenic variant Correlation between clinical features and pathogenic variants A total of 280 patients were included in this study, consisting of 180 males (64.28%) and 100 females (35.72%). The mean age at diagnosis (mean ± SD) was 39.94 ± 29.69 months. Regarding delivery mode, 168 patients (60%) had spontaneous labor, while 112 patients (40%) underwent caesarean section. For gestational age, 44 patients (15.71%) were born prematurely, and 236 patients (84.29%) were full-term births. Thirty-eight patients (13.57%) had low birth weight, while 242 patients (86.43%) had normal birth weight. Fifty-five patients (19.64%) experienced hypoxia, and 225 patients (80.36%) did not. Jaundice was present in 42 patients (15.00%), whereas 238 patients (85.00%) did not exhibit jaundice after birth. Anomalous facial features were the most common symptom, observed in 29 patients (10.36%), followed by abnormal head appearance in 18 patients (7.20%). We also identified single transverse palmar crease in 2 patients (0.71%), polydactyly in 2 patients (0.71%), and skin stain in 1 patient (0.36%) among the subjects. The family history survey revealed abnormal findings in 69 patients, including consanguineous marriages, siblings with a history of abnormal development, and immediate family members with mental retardation. In the manual myodynamia and muscle tone examination, 138 patients (49.29%) exhibited decreased myodynamia, 64 patients (22.86%) had decreased muscle tone, and 68 patients (24.29%) showed increased muscle tone. Epilepsy was the most common comorbidity, followed by congenital heart disease, including atrial septal defect (9 patients, 3.21%), ventricular septal defect (3 patients, 1.07%), patent foramen ovale (2 patients, 0.71%), tricuspid regurgitation (2 patients, 0.71%), patent ductus arteriosus (1 patient, 0.36%), and complete left bundle branch block (1 patient, 0.36%). Other comorbidities observed included cryptorchidism (4 patients, 1.43%), elevated aminotransferase levels (2 patients, 0.71%), hemangioma (2 patients, 0.71%), eczema (1 patient, 0.36%), sexual precocity (1 patient, 0.36%), and renal pelvis separation (1 patient, 0.36%). Brain MRI was performed in all patients, revealing that 222 patients (79.29%) had normal results, while 58 patients (20.71%) exhibited abnormal lesions, including intracerebral hemorrhage, hypoxic brain injury, periventricular leukomalacia, and corpus callosum hypoplasia/agenesis. EEG results were normal in 222 patients (79.29%) and abnormal in 58 patients (20.71%). Abnormal EEG findings included biased background activity and focal interictal epileptiform discharges. All of these patients underwent karyotype analysis before WES testing, but chromosome microarray analysis was not performed. Chromosomal abnormalities were identified in 10 patients (0.04%), with the following karyotypes: 46,XX, inv [9](p12q13) (2 cases), 46,XX, der [1]t(1:?)(q44:?), 46,XX, der [2]t(2:?)(p21:?), 46,X, del(X)(p21), 46,XY, del [9](p22), 46,XX, inv [9](p11q13), 46,XY, add [10](q26), 46,XX,-22,+mar(32)/(46),XX [18], 46,X, inv(Y)(p11.2q11.23). Assessment of the severity of DD/ID indicated that 116 patients (41.43%) had mild cases, 123 patients (43.93%) had moderate cases, and 41 patients (14.64%) had profound cases (Table 3). We analyzed the clinical features influencing the WES results (Table 3). Age, sex, gestational age, birth weight, anoxia, jaundice, associated symptoms, family history, myodynamia, muscle tone, epilepsy, brain MRI, EEG, and severity of DD/ID did not significantly impact WES outcomes. However, among the delivery modes, 27 (56.25%) of 48 patients who underwent caesarean section had positive WES results, compared to 85 patients (36.64%) who had negative results. Therefore, delivery mode was identified as a significant factor associated with positive WES outcomes (p = 0.012). Table 3Demographic characteristics of patients (N = 280)CharacteristicsN(%)Positive(n = 48)Negative(n = 232)P-valueSexMale180(16.64)251550.053Female100(83.36)23770.053Mean age(years)39.94 ± 29.6930.06 ± 25.7940.76 ± 30.39Delivery modeSpontaneous labor168(60.00)211470.012Caesarean section112(40.00)27850.012Gestational ageBorn prematurly44(15.71)7370.813Full-term birth236(84.29)411950.813Birth weightLow38(13.57)4340.351Normal242(86.43)441980.351AnoxiaPositive55(19.64)8470.569Negative225(80.36)401850.569IcterusPositive42(15.00)7350.929Negative238(85.00)411970.929Associated symptomsAbnormal head appearance18(7.20)5130.216Anomalous facies29(10.36)3260.297Single transverse palmar crease2(0.71)021.000polydactyly2(0.71)110.767Skin stain1(0.36)011.000Normal228(81.43)391890.972Family historyAbnormal56(20.00)9470.812Normal224(80.00)391850.812MyodynamiaReduced138(49.29)291090.090Normal142(50.71)191230.090Muscular toneReduced64(22.86)13510.444Increased68(24.29)14540.386Normal148(52.85)211270.165ComorbiditiesEpilepsy7(2.50)340.098Atrial septal defect9(3.21)271.000Ventricular septal defect3(1.07)031.000Patent ductus arteriosus1(0.36)100.171Patent foramen ovale2(0.71)100.171Tricuspid regurgitation2(0.71)100.171Complete left bundle branch block1(0.36)011.000Renal pelvis separation1(0.36)011.000Cryptorchidism4(1.43)220.277Increased aminotransferase2(0.71)021.000Cutaneous hemangioma2(0.71)110.767Eczema1(0.36)100.171Sexual precocity1(0.36)011.000Brain MRIAbnormal131(46.79)281030.078Normal149(53.21)201290.078EEGAbnormal58(20.71)12460.421Normal222(79.29)361860.421Karyotype analysisAbnormal10(0.04)281.000Normal270(0.96)462241.000Severity of DD/IDMild116(41.43)17990.353Moderate123(43.93)221010.770Profound41(14.64)9320.377MRI: magnetic resonance imaging; EEG: electroencephalography; DD: developmental delay; ID: intellectual disability. Values represent mean ± standard deviation; N, number (%); Statistical significance was set at P < 0.05 Demographic characteristics of patients (N = 280) MRI: magnetic resonance imaging; EEG: electroencephalography; DD: developmental delay; ID: intellectual disability. Values represent mean ± standard deviation; N, number (%); Statistical significance was set at P < 0.05 Discussion In our study, we analyzed the genetic causes of DD/ID using WES, yielding a diagnostic rate of 22.87% after exclusion of carriers, which is lower than the rates reported in several prior studies. For example, a 2023 study from Korea identified pathogenic variants in 48.8% of 41 patients with unexplained DD/ID [12]. Similarly, a Japanese study conducted on 101 patients with genetically undefined disorders, including symptoms such as autistic disorder (ASD), seizures, hypotonia, facial dysmorphism, and neuroimaging abnormalities, reported a diagnostic yield of 53.3% using WES [13]. Furthermore, the diagnostic rate of WES has been estimated to range from 27 to 55% across various studies [14]. Previous research has shown that WES has a higher diagnostic yield in patients with neurological deficits, multiple congenital anomalies, and more severe symptoms, emphasizing the importance of patient selection [15]. However, in our study, the lower diagnostic yield may be attributed to the lack of additional phenotypic features beyond DD/ID, which limits the effectiveness of comprehensive WES analysis. Moreover, WES has certain limitations, such as the inability to detect intronic variants, trinucleotide repeat expansions, methylation abnormalities, and only limited detection of copy number variations. Additionally, the specificity of clinical manifestations, genetic heterogeneity of the disorder, patient selection, and differences in filtering and interpreting variants contribute to the difficulty in comparing diagnostic yields across studies [14, 16]. It is noteworthy that we identified likely pathogenic variants in 16.43% of patients and variants of unknown significance in 53.57%, suggesting that our diagnostic rate may increase over time as variant reclassification and re-analysis are conducted. Trio-based exome sequencing has shown great potential in identifying de novo mutations and pathogenic genes, and the diagnostic yield for DD/ID can be enhanced as our understanding of genetic etiology advances. Furthermore, exome-based CNV analysis in our study identified 25 pathogenic CNVs, increasing the diagnostic yield by 8.93%. This finding aligns with recent studies indicating that the inclusion of exome-based CNV detection can improve the diagnostic rate of trio-WES by 18.92% in patients with NDDs [17]. CMA and CNV-seq are reported to account for approximately 10–20% of cases of intellectual disability (ID) [18]. The combination of WES with CNV-seq has been employed to maximize the molecular diagnosis of NDDs, including DD and ID. In a cohort of 113 patients with NDDs, the “WES + CNV-seq” strategy resulted in a higher diagnostic rate (47.8%) compared to the “WES-only” strategy (32.7%) [19]. Another study involving 31 individuals with NDDs showed an improvement in the diagnostic rate from 44.4% with trio-WES to 57.4% with the “trio-WES + CNV-seq” strategy [20]. The integration of exome-based CNV detection into conventional SNV/Indel analysis for a single trio-WES test significantly enhances the diagnostic yield, making WES a more powerful, practical, and cost-effective tool in the clinical diagnosis of NDDs. However, it is important to recognize that CNV detection from WES data may have limitations, including high false-positive rates and low sensitivity [21]. Therefore, pathogenic CNVs should be considered in undiagnosed patients, and re-analysis using other technologies may be necessary for rare variants. Our study demonstrated a correlation between delivery mode and positive WES results. Specifically, a higher diagnostic yield was observed in patients delivered via caesarean section, with 56.25% of the 48 patients showing positive results, compared to 36.64% with negative results. Certain fetal factors, such as labor dystocia, abnormal or indeterminate fetal heart rate patterns, fetal malpresentation, multiple gestation, and suspected fetal macrosomia, may increase the risk of vaginal delivery, often necessitating cesarean Sect. [22]. Nevertheless, fetuses with genetic abnormalities are at a heightened risk of experiencing delivery complications due to factors such as congenital defects, abnormal fetal growth, and other health-related challenges. A study on women with osteogenesis imperfecta indicated an elevated risk of complications, including antepartum hemorrhage, placental abruption, and intrauterine growth restriction, underscoring that genetic disorders in either the fetus or the mother can exacerbate delivery risks [23]. Research into genetic predispositions to preterm birth suggests that genetic factors contribute to an increased risk of preterm deliveries, further complicating the delivery process through mechanisms such as infection and inflammation [24]. In conclusion, fetuses with genetic conditions are predisposed to a greater risk of delivery complications, often leading to higher rates of cesarean sections. However, this finding differs from previous studies that identified other clinical features associated with positive WES results. For instance, a study of 41 Korean patients with unexplained DD or ID using WES found that age at symptom onset and facial dysmorphism were strongly correlated with positive WES results [12]. Another study involving 101 Japanese patients identified ASD and external ear anomalies as the most strongly associated clinical features with positive WES results, albeit weakly [13]. These findings highlight that the clinical features of DD/ID patients with positive genetic test results vary widely, underscoring the importance of detailed history-taking and physical examination in the search for causative genetic variants. Our study has several limitations. First, it was conducted at a single center, as WES is a cost-intensive procedure. However, our findings are relevant to the genetic mutations associated with DD/ID and may have implications for East Asian countries and other regions with higher incidence rates. Second, this study was conducted retrospectively at a tertiary hospital, likely resulting in the inclusion of a highly selected group of patients with relatively severe DD/ID. Nonetheless, primary care hospitals may find this study informative when diagnosing unexplained DD/ID. Finally, due to the unavailability of DNA from one or both parents or difficulties in obtaining consent, family-based trio Sanger validation could not be performed on all patients. Despite these limitations, our findings can guide clinicians in determining which patients should undergo WES. Conclusions WES is a valuable tool for identifying genetic causes in patients with unexplained DD and ID. It plays a crucial role in patient management, family genetic counseling, and long-term prognosis analysis. As next-generation sequencing (NGS) technology and genetic data analysis techniques continue to evolve, WES will have the potential to identify novel genes and variants, cover a broader range of variant types, and further enhance clinical diagnostic capabilities. Acknowledgements Not applicable. Abbreviations Developmental delay (DD) Intellectual disability Neurodevelopmental disorders Whole exome sequencing Copy number variation sequencing Single nucleotide variation Copy number variations Chromosomal microarray analysis Magnetic resonance imaging Electroencephalography Autistic disorder Author contributions JX and HL designed and conducted the study. YW and YL collected data. FY, YX and LC analyzed the data from genetic studies. JX and WS drafted the manuscript and performed the statistical analyses of the study. All the authors have read and approved the final manuscript. Funding Not applicable. Data availability The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in controlled access data storage at Anhui Provincial Children’s Hospital. Declarations Ethics approval and consent to participate The studies involving human participants were reviewed and approved by the institutional ethics committee of the Anhui Provincial Children’s Hospital. Written informed consent to participate in this study was provided by the participants’legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minors’legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article. Consent for publication No individual person’s data in any form was contained in this study. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in controlled access data storage at Anhui Provincial Children’s Hospital.